Lamor Corporation Aquaculture Solutions Lower Cost & Carbon Footprint With More Efficient Systems

PORVOO, Finland, Sept. 21, 2021 (GLOBE NEWSWIRE) — Lamor Corporation provides Reverse Osmosis-systems for brackish and seawater treatment. Finland has been one of the leading countries in cruise vessel  construction for decades, and various large cruise companies such as Royal Caribbean, TUI and Carnival have purchased their vessels from Finnish shipyards. For years cruise line companies […]

Read More

Eco-Friendly Healthcare Company Dassiet Revolutionises Fracture Treatment With New Product Line UCAST

The new cast, consisting of biodegradable Woodcast material and self-adhesive Unitex fabric, makes casting significantly faster and safer. UCAST Wrist Splint ESPOO, Finland, Sept. 21, 2021 (GLOBE NEWSWIRE) — Today, the materials company Dassiet is launching UCAST – a product line targeted towards hospitals and health centres, making fracture treatment faster and safer both for […]

Read More

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & […]

Read More

WillScot Mobile Mini Acquires Three Leading Regional Storage Services Companies

PHOENIX, Sept. 20, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced that it closed the acquisitions of American Mobile Leasing, Inc., Equipe Container Services, Inc. d/b/a Moveable Container Storage (MCS), and Saf-T-Box, LP. […]

Read More

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021 Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment $355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential WALTHAM, […]

Read More